This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guadagni, F. Articles by Schlom, J. Search for Related Content PubMed PubMed Citation Articles by Guadagni, F. Articles by Schlom, J.

CA 72-4 Measurement of Tumor-associated Glycoprotein 72 (TAG-72) as a Serum Marker in the Management of Gastric Carcinoma¹

I Department of Surgery [M. Co., P. P., R. C.], Department of Digestive Endoscopy [V. C.], and II Department of Surgery [M. Ca., E. S.], Regina Elena Cancer Institute [F. G., T. A.], and Department of Surgery, II University of Rome, School of Medicine [M. R.], Rome, Italy, and Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [J. W. G., J. S.]

The presence of three distinct serum markers of carcinoma, tumor-associated glycoprotein 72 (TAG-72; as measured by the CA 72-4 assay), CA 19-9, and carcinoembryonic antigen (CEA), was evaluated in 194 patients diagnosed with either malignant (n = 94) or benign (n = 100) gastric disease. Of the 94 patients diagnosed with gastric carcinoma, the percentage of patients whose serum samples were positive for TAG-72, CA 19-9, or CEA was 42.6, 31.9, and 20.2%, respectively. Furthermore, fewer false positive samples were observed for TAG-72 than either CA 19-9 or CEA. The analysis of serum TAG-72, CA 19-9, and CEA levels in patients diagnosed with early (stage I and II) versus advanced (stage III and IV) disease revealed a significantly higher level of TAG-72 and CA 19-9 in the serum of patients with advanced stage gastric carcinoma. The serum samples were also analyzed to determine whether any advantage might be gained by simultaneously measuring two or more of the tumor markers. The data clearly indicate that the measurement of TAG-72 with CA 19-9 significantly increased the percentage of gastric carcinoma patients with positive serum levels of either antigen. This advantage was achieved with no significant increase in the number of false positives. Twenty-one patients were followed postsurgically for up to 3 years to determine whether the appearance or reappearance of TAG-72, CA 19-9, or CEA accurately predicted disease recurrence. Positive serum TAG-72 levels correlated with disease recurrence in 7 of 10 patients, compared with 5 and 2 patients for CA 19-9 and CEA, respectively. The findings suggest that serum TAG-72 as measured by the CA 72-4 assay may be a useful marker for late stage gastric carcinoma and its measurement alone or in combination with CA 19-9 may have utility in the clinical management of gastric carcinoma.

¹ This work has been partially supported by a grant from A.I.R.C., 1991.

² To whom requests for reprints should be addressed, at Laboratory of Tumor Immunology and Biology, Building 10, Room B807, National Cancer Institute, NIH, Bethesda, MD 20892.

Received 10/14/91. Accepted 12/17/91.

This article has been cited by other articles:

				S.-X. Qiao, M. Yuan, Y.-L. Liu, X.-S. Lin, X.-P. Zhang, and M. Tobi Detection of Gastric Cancer and Premalignant Lesions by Novel Marker Glycoprotein 87 Using Monoclonal Antibody Adnab-9 Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1095 - 1099. [Abstract] [Full Text] [PDF]